Live Webinar
26 June | 4 pm CEST | 10 am EDT

Informed Risk Assessment:
Leveraging Preclinical Safety Intelligence to anticipate Clinical Adverse Events

One of the biggest challenges the pharma industry continues to face today is the failure of drug candidates due to unexpected adverse reactions. Late-stage clinical attrition for safety reasons represents a high risk in terms of patient safety and cost. Early anticipation of safety issues enables informed decisions.

In this session we will present how OFF-X's analytic tools and curated data from a broad range of sources can help de-risk drug development.

Agenda:
 
  • Challenges the pharma industry continues to face today 
  • How the safety intelligence tool OFF-X can help de-risk drug development
    • Drug - Semagacestat
    • Target – BTK inhibitors
    • Target- 4-1BB activators
  • Summary
  • Q&A

Register below

HIDDEN FIELDS BELOW

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library

Meet our speakers

Kinsi Oberoi ​
Senior Solution Consultant​


Kinsi Oberoi is a bioinformatician by training with a background in genomic research and a keen interest for continued learning about upcoming research. Kinsi started with Clarivate in 2018 and is currently working as a Senior solution consultant with experience in the life sciences industry for more then a decade.